热门出版物 - 学术资源搜索

h5 指数:148
h5 中位数:255

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#7 Oncology

标题/作者	引用次数	年份
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ... JAMA Oncology 4 (12), 1721-1728	1584	2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ... JAMA Oncology 4 (5), e180013-e180013	1419	2018
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study C Fitzmaurice, TF Akinyemiju, FH Al Lami, T Alam, R Alizadeh-Navaei, ... JAMA Oncology 4 (11), 1553-1568	1251	2018
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China J Yu, W Ouyang, MLK Chua, C Xie JAMA Oncology 6 (7), 1108-1110	1104	2020
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis R Barroso-Sousa, WT Barry, AC Garrido-Castro, FS Hodi, L Min, IE Krop, ... JAMA Oncology 4 (2), 173-182	837	2018
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer K Haratani, H Hayashi, Y Chiba, K Kudo, K Yonesaka, R Kato, H Kaneda, ... JAMA Oncology 4 (3), 374-378	758	2018
Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial P Iyengar, Z Wardak, DE Gerber, V Tumati, C Ahn, RS Hughes, JE Dowell, ... JAMA Oncology 4 (1), e173501-e173501	745	2018
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial DA Reardon, AA Brandes, A Omuro, P Mulholland, M Lim, A Wick, ... JAMA Oncology 6 (7), 1003-1010	707	2020
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... JAMA Oncology 6 (11), e204564-e204564	670	2020
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial GW Sledge, M Toi, P Neven, J Sohn, K Inoue, X Pivot, O Burdaeva, ... JAMA Oncology 6 (1), 116-124	633	2020
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial R Phillips, WY Shi, M Deek, N Radwan, SJ Lim, ES Antonarakis, SP Rowe, ... JAMA Oncology 6 (5), 650-659	633	2020
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial WSME Theelen, HMU Peulen, F Lalezari, V van der Noort, JF de Vries, ... JAMA Oncology 5 (9), 1276-1282	619	2019
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ... JAMA Oncology 4 (11), 1543-1552	614	2018
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer L Mezquita, E Auclin, R Ferrara, M Charrier, J Remon, D Planchard, ... JAMA Oncology 4 (3), 351-357	582	2018
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study LA Emens, C Cruz, JP Eder, F Braiteh, C Chung, SM Tolaney, I Kuter, ... JAMA Oncology 5 (1), 74-82	580	2019
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial K Shitara, E Van Cutsem, YJ Bang, C Fuchs, L Wyrwicz, KW Lee, ... JAMA Oncology 6 (10), 1571-1580	557	2020
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib GR Oxnard, Y Hu, KF Mileham, H Husain, DB Costa, P Tracy, N Feeney, ... JAMA Oncology 4 (11), 1527-1534	531	2018
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer T Reinert, TV Henriksen, E Christensen, S Sharma, R Salari, H Sethi, ... JAMA Oncology 5 (8), 1124-1131	527	2019
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis Y Wang, S Zhou, F Yang, X Qi, X Wang, X Guan, C Shen, N Duma, ... JAMA Oncology 5 (7), 1008-1019	523	2019
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016 AJ Cowan, C Allen, A Barac, H Basaleem, I Bensenor, MP Curado, ... JAMA Oncology 4 (9), 1221-1227	508	2018

1 - 20

计算机程序会自动估算并确定日期和引用次数。